dosing, BMD, symptomatic or asymptomatic vertebral compression fractures) should be taken into account when considering assessment for OP therapy * As in prior guidelines, we used risk categories of low, moderate, and high using DXA and/or FRAX assessments (see Table 1 2 For adults continuing chronic GC â‰¥2.5 mg/day but <7.5 mg/day and assessed as low fracture risk, who were not recommended to start therapy, or moderate fracture risk who chose not to start OP therapy (except calcium and vitamin